FDA Approval of Nivolumab for Stage III Melanoma: What it Means for the Immunotherapy Revolution
With the recent FDA approval of the drug nivolumab (Opdivo®, previously approved for stage IV melanoma) as a treatment for stage III melanoma, we have reached the next important phase in the immunotherapy revolution. It is a revolution that most of the world’s top experts believe will one day, very possibly within a decade, turn advanced (stages III and IV) melanoma into a chronic, or even curable, disease rather than a deadly one. Read more - https://blog.skincancer.org/2018/01/19/fda-approval-nivolumab-immunotherapy/